Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Mar;147(3):233-238.
doi: 10.4103/ijmr.IJMR_652_17.

Host-targeted therapy for tuberculosis: Time to revisit the concept

Prabha Desikan  1 , Aseem Rangnekar  1
Affiliations
Review

Host-targeted therapy for tuberculosis: Time to revisit the concept

Prabha Desikan et al. Indian J Med Res. 2018 Mar.

Abstract

Tuberculosis (TB) is an important cause of morbidity and mortality worldwide. Every year millions of people die due to TB. Drug resistance has been a major factor that has obstructed successful control and treatment of TB. As the rate of spread of drug-resistant TB outpaces the rate of discovery of new anti-tubercular drugs, targeted therapy may provide a new approach to TB cure. In a scenario where drug resistance is spreading rapidly, and existing drugs regimens seem to be dwindling away, this review summarizes the concept of host-targeted therapy which may be the ray of hope for the effective management and control of the rapidly spreading drug-resistant TB (multidrug resistant and extensively drug resistant).

Keywords: Host-targeted therapy; VEGF; micro RNA; multidrug-resistant/extensively drug-resistant TB.

PubMed Disclaimer

Conflict of interest statement

None

Similar articles

See all similar articles

Cited by

References

    1. World Health Organization. Global tuberculosis report 2016. Geneva: World Health Organization; 2016.
    1. Hoagland DT, Liu J, Lee RB, Lee RE. New agents for the treatment of drug-resistant Mycobacterium tuberculosis. Adv Drug Deliv Rev. 2016;102:55–72. - PMC - PubMed
    1. Luciani F, Sisson SA, Jiang H, Francis AR, Tanaka MM. The epidemiological fitness cost of drug resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 2009;106:14711–5. - PMC - PubMed
    1. Working Group on New TB Drugs. Press Release from Infectex and Sequella on SQ-109 Clinical trial in Russia; 22 March. 2017. [accessed on April 19, 2017]. Available from: http://www.newtbdrugs.org .
    1. World Health Organization. Interim guidance on the use of bedaquiline to treat MDR-TB. [accessed on April 19, 2017]. Available from: http://www.who.int/tb/challenges/mdr/bedaquiline/en/

Substances